Cargando…

Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance

The bacterial metallo-β-lactamases (MBLs) catalyze the inactivation of β-lactam antibiotics. Identifying novel pharmacophores remains crucial for the clinical development of additional MBL inhibitors. Previously, 1-hydroxypyridine-2(1H)-thione-6-carboxylic acid, hereafter referred to as 1,2-HPT-6-CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Thoden, James B., Benin, Bogdan M., Priebe, Adam, Shin, Woo Shik, Muthyala, Ramaiah, Sham, Yuk Yin, Holden, Hazel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514461/
https://www.ncbi.nlm.nih.gov/pubmed/37549809
http://dx.doi.org/10.1016/j.jbc.2023.105135
_version_ 1785108733607542784
author Thoden, James B.
Benin, Bogdan M.
Priebe, Adam
Shin, Woo Shik
Muthyala, Ramaiah
Sham, Yuk Yin
Holden, Hazel M.
author_facet Thoden, James B.
Benin, Bogdan M.
Priebe, Adam
Shin, Woo Shik
Muthyala, Ramaiah
Sham, Yuk Yin
Holden, Hazel M.
author_sort Thoden, James B.
collection PubMed
description The bacterial metallo-β-lactamases (MBLs) catalyze the inactivation of β-lactam antibiotics. Identifying novel pharmacophores remains crucial for the clinical development of additional MBL inhibitors. Previously, 1-hydroxypyridine-2(1H)-thione-6-carboxylic acid, hereafter referred to as 1,2-HPT-6-COOH, was reported as a low cytotoxic nanomolar β-lactamase inhibitor of Verona-integron-encoded metallo-β-lactamase 2, capable of rescuing β-lactam antibiotic activity. In this study, we explore its exact mechanism of inhibition and the extent of its activity through structural characterization of its binding to New Delhi metallo-β-lactamase 4 (NDM-4) and its inhibitory activity against both NDM-1 and NDM-4. Of all the structure-validated MBL inhibitors available, 1,2-HPT-6-COOH is the first discovered compound capable of forming an octahedral coordination sphere with Zn2 of the binuclear metal center. This unexpected mechanism of action provides important insight for the further optimization of 1,2-HPT-6-COOH and the identification of additional pharmacophores for MBL inhibition.
format Online
Article
Text
id pubmed-10514461
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-105144612023-09-23 Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance Thoden, James B. Benin, Bogdan M. Priebe, Adam Shin, Woo Shik Muthyala, Ramaiah Sham, Yuk Yin Holden, Hazel M. J Biol Chem Research Article The bacterial metallo-β-lactamases (MBLs) catalyze the inactivation of β-lactam antibiotics. Identifying novel pharmacophores remains crucial for the clinical development of additional MBL inhibitors. Previously, 1-hydroxypyridine-2(1H)-thione-6-carboxylic acid, hereafter referred to as 1,2-HPT-6-COOH, was reported as a low cytotoxic nanomolar β-lactamase inhibitor of Verona-integron-encoded metallo-β-lactamase 2, capable of rescuing β-lactam antibiotic activity. In this study, we explore its exact mechanism of inhibition and the extent of its activity through structural characterization of its binding to New Delhi metallo-β-lactamase 4 (NDM-4) and its inhibitory activity against both NDM-1 and NDM-4. Of all the structure-validated MBL inhibitors available, 1,2-HPT-6-COOH is the first discovered compound capable of forming an octahedral coordination sphere with Zn2 of the binuclear metal center. This unexpected mechanism of action provides important insight for the further optimization of 1,2-HPT-6-COOH and the identification of additional pharmacophores for MBL inhibition. American Society for Biochemistry and Molecular Biology 2023-08-06 /pmc/articles/PMC10514461/ /pubmed/37549809 http://dx.doi.org/10.1016/j.jbc.2023.105135 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Thoden, James B.
Benin, Bogdan M.
Priebe, Adam
Shin, Woo Shik
Muthyala, Ramaiah
Sham, Yuk Yin
Holden, Hazel M.
Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance
title Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance
title_full Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance
title_fullStr Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance
title_full_unstemmed Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance
title_short Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance
title_sort characterization of a novel inhibitor for the new delhi metallo-β-lactamase-4: implications for drug design and combating bacterial drug resistance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514461/
https://www.ncbi.nlm.nih.gov/pubmed/37549809
http://dx.doi.org/10.1016/j.jbc.2023.105135
work_keys_str_mv AT thodenjamesb characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance
AT beninbogdanm characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance
AT priebeadam characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance
AT shinwooshik characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance
AT muthyalaramaiah characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance
AT shamyukyin characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance
AT holdenhazelm characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance